ArticleThe Annals of pharmacotherapy2023

Reply: Baricitinib Versus Tocilizumab for the Treatment of Moderate to Severe COVID-19.

Temeka Dawn Lewis-Wolfson et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.